PETALING JAYA: Duopharma Biotech Bhd
, which released the company’s fourth quarter ended Dec 31, 2024 (4Q24) and full-year financial results on Wednesday, is expected to see further earnings growth in FY25 on higher government healthcare allocation and lower active pharmaceutical ingredient (API) prices.
Analysts expect stronger earnings growth from 1Q25 onwards, with TA Securities Research pointing out that the performance would be driven by higher public sector demand from the renewal of the approved products list (APPL) from last May, a new government contract to supply insulin and lower API prices.
